New Delay For Teva's Generic Lovenox Bodes Well For Sandoz/Momenta Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
A "minor deficiency letter" from FDA's Office of Generic Drugs seeks responses to questions about Teva's enoxaparin ANDA, the company says.
You may also be interested in...
Generic Lovenox Battle Heats Up With Amphastar’s ANDA Approval
Momenta Pharmaceuticals and Sandoz have enjoyed approximately 14 months of de facto generic exclusivity on Sanofi’s anticoagulant Lovenox (enoxaparin), but faced with the imminent threat of competition they are trying to maintain their hold on the market through patent litigation.
Generic Lovenox Battle Heats Up With Amphastar’s ANDA Approval
Momenta Pharmaceuticals and Sandoz have enjoyed approximately 14 months of de facto generic exclusivity on Sanofi’s anticoagulant Lovenox (enoxaparin), but faced with the imminent threat of competition they are trying to maintain their hold on the market through patent litigation.
Amphastar Seeks Court Order Requiring FDA To Approve Its Enoxaparin ANDA
Amphastar’s initial lawsuit against FDA achieved its stated goal: the agency released two shipments of raw heparin material the company is to use in producing generic Lovenox (enoxaparin).